JP2024527220A5 - - Google Patents
Info
- Publication number
- JP2024527220A5 JP2024527220A5 JP2023566569A JP2023566569A JP2024527220A5 JP 2024527220 A5 JP2024527220 A5 JP 2024527220A5 JP 2023566569 A JP2023566569 A JP 2023566569A JP 2023566569 A JP2023566569 A JP 2023566569A JP 2024527220 A5 JP2024527220 A5 JP 2024527220A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pro
- peptide
- composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2021-0086014 | 2021-06-30 | ||
| KR1020210086014A KR20230004135A (ko) | 2021-06-30 | 2021-06-30 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
| PCT/KR2022/009449 WO2023277620A1 (ko) | 2021-06-30 | 2022-06-30 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527220A JP2024527220A (ja) | 2024-07-24 |
| JP2024527220A5 true JP2024527220A5 (cg-RX-API-DMAC7.html) | 2025-07-07 |
Family
ID=84690475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566569A Pending JP2024527220A (ja) | 2021-06-30 | 2022-06-30 | グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体を含む組み合わせ物の治療学的用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240293512A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4364750A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527220A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230004135A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117615775A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022302809A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023022445A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3216330A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308347A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012935A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023277620A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| JP6712323B2 (ja) * | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体 |
| SG10202109721PA (en) * | 2016-03-10 | 2021-10-28 | Medimmune Ltd | Glucagon and glp-1 co-agonists for the treatment of obesity |
| JOP20190095A1 (ar) * | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| JP7005638B2 (ja) * | 2017-01-27 | 2022-02-04 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | グルカゴン受容体結合タンパク質及びその使用方法 |
| WO2020071865A1 (ko) * | 2018-10-04 | 2020-04-09 | 한미약품 주식회사 | 글루카곤 및 이를 포함하는 조합물의 치료학적 용도 |
| WO2020130749A1 (ko) * | 2018-12-21 | 2020-06-25 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물 |
| WO2020142365A1 (en) * | 2018-12-31 | 2020-07-09 | Christos Mantzoros | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| MX2021015927A (es) * | 2019-06-28 | 2022-04-18 | Hanmi Pharm Ind Co Ltd | Uso terapéutico de agonista trigonal de los receptores de glucagón, glp-1 y gip, o conjugado de los mismos para enfermedades hepáticas. |
| JP2023537895A (ja) * | 2020-08-14 | 2023-09-06 | ハンミ ファーマシューティカル カンパニー リミテッド | 三重活性体持続型結合体を有効成分として含む薬学組成物 |
-
2021
- 2021-06-30 KR KR1020210086014A patent/KR20230004135A/ko active Pending
-
2022
- 2022-06-30 AU AU2022302809A patent/AU2022302809A1/en active Pending
- 2022-06-30 BR BR112023022445A patent/BR112023022445A2/pt unknown
- 2022-06-30 JP JP2023566569A patent/JP2024527220A/ja active Pending
- 2022-06-30 US US18/565,628 patent/US20240293512A1/en active Pending
- 2022-06-30 WO PCT/KR2022/009449 patent/WO2023277620A1/ko not_active Ceased
- 2022-06-30 MX MX2023012935A patent/MX2023012935A/es unknown
- 2022-06-30 IL IL308347A patent/IL308347A/en unknown
- 2022-06-30 CN CN202280042772.4A patent/CN117615775A/zh active Pending
- 2022-06-30 CA CA3216330A patent/CA3216330A1/en active Pending
- 2022-06-30 EP EP22833674.9A patent/EP4364750A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7341263B2 (ja) | オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物 | |
| JP6076902B2 (ja) | 新規な持続型グルカゴン結合体およびこれを含む肥満の予防および治療用薬学的組成物 | |
| KR101201339B1 (ko) | 인간 epo 미메틱 힌지 코어 미메티바디, 조성물, 방법및 용도 | |
| JP2020164534A (ja) | インスリン及びglp−1/グルカゴン二重アゴニストを含む糖尿病治療用組成物 | |
| US8097586B2 (en) | Modified exedins and uses thereof | |
| US8716221B2 (en) | Modified exendins and uses thereof | |
| IL260310B1 (en) | Long-term coupling of a triple agonist to glucagon/GLP–1/GIP receptors | |
| KR20050033563A (ko) | 포유동물 epo 모방 ch1 결실된 모방체, 조성물, 방법및 용도 | |
| JP2006520818A (ja) | ポリエチレングリコール結合glp−1化合物 | |
| PT2356269T (pt) | Composições, métodos e usos de scaffolds baseados em domínios de fibronectina tipo iii | |
| JP7762645B2 (ja) | バリアントfcドメイン及びその使用 | |
| JP2022551282A5 (cg-RX-API-DMAC7.html) | ||
| RU2677800C2 (ru) | Сайт-специфичный конъюгат инсулина | |
| JP2007514752A (ja) | Glp−1医薬組成物 | |
| JP2024512418A (ja) | 新規な免疫活性インターロイキン2アナログ結合体及びその製造方法 | |
| TWI922560B (zh) | 新穎之三重升糖素/glp-1/gip受體促效劑及其用途 | |
| JP2024178193A (ja) | インスリン及びグルカゴンを含む薬学組成物 | |
| JP2024500605A5 (cg-RX-API-DMAC7.html) | ||
| JP2024525213A5 (cg-RX-API-DMAC7.html) | ||
| JP2024507795A (ja) | グルカゴン様ペプチド-1受容体アンタゴニスト | |
| JP2023538236A5 (cg-RX-API-DMAC7.html) | ||
| JP2023537895A5 (cg-RX-API-DMAC7.html) | ||
| WO2025157263A1 (zh) | 偶联物及其制备方法和用途 | |
| EP4364750A1 (en) | Therapeutic use of combination comprising triple activator having activity on all of glucagon, glp-1 and gip receptor | |
| AU2021409610A1 (en) | Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome |